Philips North America has been the subject of 355 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles.
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles: 0 warning letters, 1 recall, 0 approval records, 0 Form 483s.
Philips North America: 0 warning letters, 355 recalls, 0 approval records, 0 Form 483s.
Side by side
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles — Warning letters0
Philips North America — Warning letters0
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles — Recalls1
Philips North America — Recalls355
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles — Approval records0
Philips North America — Approval records0
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles — Form 483s0
Philips North America — Form 483s0
Timeline
Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles
Most recent FDA action: May 13, 2026
Full history →Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles vs Philips North America: FDA Enforcement Comparison." Argus HQ, accessed August 27, 2026. https://argushq.ai/compare/central-admixture-pharmacy-services-inc-caps-los-angeles-vs-philips-north-america
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗